Vaxcyte (PCVX) Operating Income (2019 - 2026)
Vaxcyte (PCVX) reported Operating Income of -$345.8 million for Q1 2026, down 91.3% year-over-year from -$4.0 billion in Q1 2025, and down 26.09% quarter-over-quarter from -$274.3 million in Q4 2025.
Vaxcyte (PCVX) Operating Income (2019 - 2026) Analysis & Trends
Vaxcyte (PCVX) has 8 years of Operating Income data on file, last reported at -$345.8 million in Q1 2026.
- Operating Income for Q1 2026 came in at -$345.8 million, down 91.3% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.1 billion (down 71.22% YoY), and the FY2025 annual result was -$923.7 million, down 62.18% from the prior year.
- Operating Income fell to -$345.8 million in Q1 2026 per PCVX's latest filing, from -$274.3 million in the prior quarter.
- Over five years, Operating Income peaked at -$39.2 million in Q1 2022 and troughed at -$345.8 million in Q1 2026.
- A 5-year average of -$149.4 million and a median of -$139.9 million in 2024 frame the typical range for Operating Income.
- The sharpest annual moves came in 2022 and 2024: Operating Income plunged 190.07% in 2022, then advanced 17.55% in 2024.
- A 5-year view of Operating Income shows it stood at -$86.6 million in 2022, then tumbled by 127.18% to -$196.7 million in 2023, then increased by 17.55% to -$162.2 million in 2024, then tumbled by 69.13% to -$274.3 million in 2025, then dropped by 26.09% to -$345.8 million in 2026.
- Business Quant data shows PCVX's Operating Income at -$345.8 million in Q1 2026, -$274.3 million in Q4 2025, and -$242.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -15.76 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -65.83 Mn |
| 10 | Vaxcyte | 6.34 Bn | 6.34 Bn | - | -345.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -345.85 Mn |
| Dec 31, 2025 | -274.28 Mn |
| Sep 30, 2025 | -242.38 Mn |
| Jun 30, 2025 | -226.22 Mn |
| Mar 31, 2025 | -180.79 Mn |
| Dec 31, 2024 | -162.17 Mn |
| Sep 30, 2024 | -139.92 Mn |
| Jun 30, 2024 | -152.98 Mn |
| Mar 31, 2024 | -114.47 Mn |
| Dec 31, 2023 | -196.68 Mn |
| Sep 30, 2023 | -113.03 Mn |
| Jun 30, 2023 | -87.15 Mn |
| Mar 31, 2023 | -71.19 Mn |
| Dec 31, 2022 | -86.57 Mn |
| Sep 30, 2022 | -58.58 Mn |
| Jun 30, 2022 | -47.89 Mn |
| Mar 31, 2022 | -39.22 Mn |
| Dec 31, 2021 | -29.85 Mn |
| Sep 30, 2021 | -26.95 Mn |
| Jun 30, 2021 | -23.73 Mn |